A pair of FDA advisory committees planned a joint meeting to discuss the pros and cons of computed tomography colonoscopy as a method of scanning asymptomatic patients for colorectal cancer, according to a notice in the Federal Register.
The FDA’s Gastroenterology-Urology Panel and the Radiological Devices Panel will join forces to advise the FDA on continuing regulation on the topic, meeting in a public forum open to "interested persons" who may present data and opinions, either in writing or orally during the meeting.
The conference is set for Sept. 9, 2013, from 8 a.m. to 6 p.m. at the FDA’s White Oak Campus in Maryland, according to the notice.
The federal watchdog agency has issued a swath of new guidances in recent months, covering a variety of healthcare issues. The FDA earlier this month issued a new draft guidance on adverse-event reporting requirements for medtech companies and finalized a researcher misconduct privacy rule.